| Literature DB >> 35264351 |
Mulate Belete Demessie1, Alemseged Beyene Berha2.
Abstract
OBJECTIVES: This study aimed to determine the prevalence, categories and predictors of drug-related hospitalisation (DRH) among patients visiting emergency departments of Addis Ababa city hospitals, Ethiopia.Entities:
Keywords: epidemiology; health & safety; quality in healthcare
Mesh:
Year: 2022 PMID: 35264351 PMCID: PMC8915323 DOI: 10.1136/bmjopen-2021-054778
Source DB: PubMed Journal: BMJ Open ISSN: 2044-6055 Impact factor: 2.692
Figure 1Patients’ inclusion information flow chart in the emergency ward at TASH, ZMH and Y12HMC, Addis Ababa, Ethiopia, August–September 2020 (n=423). DRH, drug-related hospitalisation; TASH, Tikur Anbessa Specialized Hospital; Y12HMC, Yekatit 12 Hospital Medical College; ZMH, Zewditu Memorial Hospital.
Sociodemographic and clinical characteristics of the participants in the emergency ward at TASH, ZMH and Y12HMC, Addis Ababa, Ethiopia, August–September 2020 (n=423)
| Variables | DRH (245), n (%) | Non-DRH (178), n (%) | Total (423), n (%) |
| Gender | |||
| 119 (48.6) | 88 (49.4) | 207 (48.9) | |
| 126 (51.4) | 90 (50.6) | 216 (51.1) | |
| Age* (in years) | |||
| 48.23±17.85 | 46.5±16.3 | 47.5±17.2 | |
| 24 (9.8) | 14 (7.9) | 38 (8.98) | |
| 51 (20.8) | 59 (33.1) | 110(26) | |
| 100 (40.8) | 74 (41.6) | 174 (41.1) | |
| 70 (28.6) | 31 (17.4) | 101 (23.9) | |
| Marital status* | |||
| 64 (26.1) | 34 (19.1) | 98 (23.2) | |
| 129 (48.6) | 105(59) | 234 (55.3) | |
| 20 (8.2) | 9 (5.1) | 29 (6.7) | |
| 42 (17.1) | 31 (16.9) | 73 (17.3) | |
| Educational level* | |||
| 116 (47.3) | 72 (40.4) | 188 (44.4) | |
| 66 (26.9) | 47 (26.4) | 113 (26.7) | |
| 31 (12.7) | 35 (19.7) | 66 (15.6) | |
| 32 (13.1) | 24 (13.5) | 56 (13.2) | |
| Residence | |||
| 177 (72.2) | 127 (71.3) | 304 (71.9) | |
| 68 (27.8) | 51 (28.7) | 119 (28.1) | |
| Religion | |||
| 186(76) | 136(76) | 322 (76.1) | |
| 42 (17.1) | 31 (17.4) | 73 (17.3) | |
| 1 (0.4) | 1 (0.6) | 2 (0.5) | |
| 16 (6.5) | 10(6) | 26 (6.1) | |
| Employment status* | |||
| 111 (45.3) | 83 (46.6) | 194 (45.9) | |
| 87 (35.5) | 74 (41.6) | 161 (38.1) | |
| 18 (7.3) | 7 (3.9) | 25 (5.9) | |
| 29 (11.8) | 14 (7.9) | 43 (10.2) | |
| Social habit (smoking cigarette) | |||
| 29 (11.8) | 15 (8.4) | 44 (10.4) | |
| 216 (88.2) | 163 (91.6) | 379 (89.6) | |
| Social habit (drinking alcohol) | |||
| 71 (29) | 57 (32) | 128 (30.3) | |
| 174 (71) | 121 (68) | 295 (69.7) | |
| Any physical activity | |||
| 170 (69.4) | 132 (74.1) | 302 (71.4) | |
| 70 (30.6) | 46 (25.9) | 106 (28.6) | |
| Home remedies (herbals) | |||
| 3 (1.2) | 0 (0) | 3 (0.7) | |
| 242 (98.8) | 178 (100) | 420 (99.3) | |
| Number of medications taken per patient* | |||
| 3.4±2.4 | 3.2±2.1 | 3.3±2.3 | |
| 24 (9.8) | 12 (6.7) | 36 (8.5) | |
| 41 (16.7) | 26 (14.6) | 67 (15.8) | |
|
| 35 (14.3) | 40 (22.5) | 75 (17.7) |
| 61 (24.9) | 57(32) | 118 (27.9) | |
| 84 (34.3) | 43 (24.2) | 127 (30) | |
| Polypharmacy | |||
| 84 (34.3) | 43 (24.2) | 127 (30) | |
| 161 (65.7) | 135 (75.8) | 296 (70) | |
| Comorbid condition* | |||
| 137 (55.9) | 76 (42.7) | 213 (50.4) | |
| 108 (44.1) | 102 (57.3) | 210 (49.6) | |
| Comorbid condition (hypertension) | |||
| 68 (27.8) | 40 (22.5) | 108 (25.5) | |
| Comorbid condition (diabetes mellitus) | |||
| 31 (12.7) | 22 (12.4) | 53 (12.5) | |
| Comorbid condition (cardiac diseases) | |||
| 38 (15.5) | 21 (11.8) | 59 (13.9) | |
*Represent variables having significant bivariate associations.
†Participants who did not have any occupation rather they lived depending on other people.
DRH, drug-related hospitalisation; TASH, Tikur Anbessa Specialized Hospital; Y12HMC, Yekatit 12 Hospital Medical College; ZMH, Zewditu Memorial Hospital.
Figure 2Numbers of drug-related problem occurrence per patient leading to hospitalisation in the emergency ward at TASH, ZMH and Y12HMC, Addis Ababa, Ethiopia, August–September 2020 (n=245). TASH, Tikur Anbessa Specialized Hospital; Y12HMC, Yekatit 12 Hospital Medical College; ZMH, Zewditu Memorial Hospital.
Categories of drug-related hospitalisation (DRH) in the emergency ward at TASH, ZMH and Y12HMC, Addis Ababa, Ethiopia, August–September 2020 (n=245)
| Categories of DRH | Causes of DRH | Frequency (%) |
| Untreated indications | 94 (38.5) | |
| Untreated medical condition existed | 34 (36.2) | |
| Synergistic/potentiating drug needed | 42 (44.7) | |
| Preventive/prophylactic drug needed | 18 (19) | |
| Improper drug selection | 16 (6.5) | |
| More effective alternative drug is available | 6 (37.5) | |
| Condition is already refractory to drug | 2 (12.5) | |
| The drug is not effective for condition | 6 (37.5) | |
| Others* | 2 (12.5) | |
| Subtherapeutic dosage | 30 (12.2) | |
| Wrong dose (too small) of the drug | 24 (80) | |
| Frequency is inappropriate (long) | 5 (16.7) | |
| Duration of drug use is too short | 1 (3.3) | |
| Supratherapeutic dosage | 13 (5.3) | |
| Wrong dose (too high) of the drug | 11 (84.6) | |
| Frequency is inappropriate (short) | 2 (15.4) | |
| Adverse drug reaction | 38 (15.5) | |
| Undesired effect from the drug is found | 34 (89.5) | |
| Unsafe drug for patient existed | 1 (2.6) | |
| Dosage is administered too rapidly | 1 (2.6) | |
| Allergic reaction is found/reported | 2 (5.3) | |
| Drug interactions | 1 (0.4) | |
| There is (are) major drug interaction/s | 1 (100) | |
| Failure to receive drugs | 130 (53.5) | |
| Does not understand instructions | 6 (4.6) | |
| Patients prefer not to take | 43 (33.1) | |
| Patients forget to take | 3 (2.3) | |
| Drug product not available | 17 (13.1) | |
| Cost of medication too expensive | 16 (12.3) | |
| Does not believe in the drug effectiveness | 1 (0.8) | |
| Patients felt better | 17 (13.1) | |
| Patients felt worse | 1 (0.8) | |
| Fear of adverse events | 18 (13.8) | |
| Failure to follow up due to COVID-19 | 8 (6.2) | |
| Total number of DRPs leading to DRH | 322 | |
| Total number of participants with DRH | 245 | |
| Average number of DRPs per drug-related hospitalised patient | 1.31 | |
| Preventability of DRH | 215 (87.8) | |
*Patients who were using expired drugs like insulin and albuterol.
DRPs, drug-related problems; TASH, Tikur Anbessa Specialized Hospital; Y12HMC, Yekatit 12 Hospital Medical College; ZMH, Zewditu Memorial Hospital.
Diseases associated with drug-related hospitalisation in the emergency ward at TASH, ZMH and Y12HMC, Addis Ababa, Ethiopia, August–September 2020 (n=245)
| Disease categories | n (%) |
| Cardiovascular diseases | 80 (32.6) |
| CNS diseases | 8 (3.2) |
| Cerebrovascular diseases | 26 (10.6) |
| Infectious diseases | 21 (8.5) |
| Endocrine system diseases | 47 (19.2) |
| Cancer | 25 (10.1) |
| Diseases of the respiratory system | 21 (8.5) |
| GI diseases | 10 (4) |
| Others* | 7 (2.8) |
*Includes anaemia, chronic kidney disease, systemic lupus erythematosus and haemophilia.
CNS, central nervous system; GI, gastrointestinal; TASH, Tikur Anbessa Specialized Hospital; Y12HMC, Yekatit 12 Hospital Medical College; ZMH, Zewditu Memorial Hospital.
Medication classes and specific drugs implicated in drug-related hospitalisation (DRH) in the emergency ward at TASH, ZMH and Y12HMC, Addis Ababa, Ethiopia, August–September 2020 (n=245)
| Drug class | Specific drugs | n (%) |
| Cardiovascular drugs | ||
| Atorvastatin | 31 (12.7) | |
| Antiplatelets (aspirin, clopidogrel) | 24 (9.8) | |
| Furosemide | 59 (24.1) | |
| Spironolactone | 33 (13.5) | |
| Anticoagulants (warfarin, heparin) | 20 (8.2) | |
| Beta-blockers (metoprolol, atenolol) | 21 (8.6) | |
| Digoxin | 15 (6.1) | |
| ACE inhibitors (enalapril/lisinopril) | 48 (19.6) | |
| Calcium channel blockers (nifedipine, amlodipine) | 34 (13.9) | |
| Hydrochlorothiazide | 11 (4.5) | |
| Drugs for the respiratory system | ||
| Long-acting beta-blockers | 15 (6.1) | |
| Bronchodilator | 10 (4.1) | |
| Central nervous system drugs | ||
| Antiepileptics | 5 (2) | |
| Antipsychotics | 5 (2) | |
| Amitriptylin | 2 (0.8) | |
| Antimicrobial drugs | ||
| Antibiotics (piperacillin/tazobactam, meropenem, amoxicillin, amoxicillin/clavunicacid, ceftriaxone, benzathine penicillin) | 25 (10.2) | |
| Combination of antiretroviral therapy | 15 (6.1) | |
| Anti-tuberculosis | 13 (5.3) | |
| Antineoplastic agents | Cyclophosphamide, imatinib, methotrexate, doxorubicin | 23 (9.4) |
| Immunosuppressants | ||
| Mycophenolate | 1(.4) | |
| Corticosteroids (prednisolone, budesonide) | 9 (3.7) | |
| Endocrine drugs | ||
| Oral hypoglycaemic drugs (metformin, glibenclamide) | 37 (15.1) | |
| Insulin | 24 (9.8) | |
| Propylthiouracil | 4 (1.6) | |
| Gastrointestinal drug | Proton pump inhibitors | 7 (2.9) |
| Others | Potassium chloride | 1 (0.4) |
| Non-steroidal anti-inflammatory drugs | 3 (1.2) | |
| Opioids | 1 (0.4) | |
| Others | ||
| Ferrous sulfate | 1 (0.4) | |
| Total number of medications involved in DRH | 497 | |
| Total number of drug-related hospitalised participants | 245 (57.9) | |
| Average number of medications per drug-related hospitalised patient | 2.03 | |
TASH, Tikur Anbessa Specialized Hospital; Y12HMC, Yekatit 12 Hospital Medical College; ZMH, Zewditu Memorial Hospital.
Predictors involved in drug-related hospitalisation (DRH) in the emergency ward at TASH, ZMH and Y12HMC, Addis Ababa, Ethiopia, August–September 2020 (n=245)
| Predictors of patient hospitalisation | OR | ||||
| DRH (245) | Non-DRH (178) | Total (423) | AOR (95% CI) | P value | |
| Variables | n (%) | n (%) | n (%) | ||
| Age (years) | |||||
| 48.24±17.86 | 47.50±17.21 | ||||
| 24 (9.8) | 14 (7.9) | 38 (8.98) | 1 | ||
| 51 (20.8) | 59 (33.1) | 110(26) | 1.55 (0.51 to 4.66) | 0.435 | |
| 100 (40.8) | 74 (41.6) | 174 (41.1) | 2.567 (0.82 to 8.06) | 0.106 | |
| 70 (28.6) | 31 (17.4) | 101 (23.9) | 7.45 (1.89 to 29.40) | 0.004 | |
| Marital status | |||||
| 64 (26.1) | 34 (19.1) | 98 (23.2) | 1 | ||
| 129 (48.6) | 105(59) | 234 (55.3) | 0.60 (0.29 to 1.23) | 0.16 | |
| 20 (8.2) | 9 (5.1) | 29 (6.7) | 0.49 (0.20 to 1.18) | 0.109 | |
| 42 (17.1) | 31 (16.9) | 73 (17.3) | 0.35 (0.19 to 0.75) | 0.983 | |
| Educational level | |||||
| 116 (47.3) | 72 (40.4) | 188 (44.4) | 1 | ||
| 66 (26.9) | 47 (26.4) | 113 (26.7) | 0.57 (0.23 to 1.43) | 0.229 | |
| 31 (12.7) | 35 (19.7) | 66 (15.6) | 0.57 (0.23 to 1.39) | 0.215 | |
| 32 (13.1) | 24 (13.5) | 56 (13.2) | 0.36 (0.14 to 0.92) | 0.033 | |
| Employment status | |||||
| 111 (45.3) | 83 (46.6) | 194 (45.9) | 1 | ||
| 87 (35.5) | 74 (41.6) | 161 (38.1) | 0.29 (0.09 to 0.89) | 1 | |
| 18 (7.3) | 7 (3.9) | 25 (5.9) | 6.33 (1.38 to 29.15) | 0.018 | |
| 29 (11.8) | 14 (7.9) | 43 (10.2) | 3.41 (1.12 to 10.37) | 0.031 | |
| Polypharmacy | |||||
| 84 (34.3) | 43 (24.2) | 127(30) | 1.48 (0.72 to 3.04) | 0.284 | |
| 161 (65.7) | 135 (75.8) | 296(70) | 1 | ||
| Comorbid condition | |||||
| 137 (55.9) | 76 (42.7) | 213 (50.4) | 2.00 (1.09 to 3.67) | 0.024 | |
| 108 (44.1) | 102 (57.3) | 210 (49.6) | 1 | ||
*Participants who did not have any occupation.
AOR, adjusted OR; TASH, Tikur Anbessa Specialized Hospital; Y12HMC, Yekatit 12 Hospital Medical College; ZMH, Zewditu Memorial Hospital.